Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ABEO | Abeona Therapeutics Inc.

Index- P/E- EPS (ttm)-3.02 Insider Own3.30% Shs Outstand24.76M Perf Week-5.96%
Market Cap95.47M Forward P/E- EPS next Y-1.96 Insider Trans0.54% Shs Float22.85M Perf Month-8.23%
Income-36.40M PEG- EPS next Q-0.53 Inst Own7.10% Short Float / Ratio2.19% / 3.50 Perf Quarter-23.74%
Sales3.60M P/S26.52 EPS this Y74.40% Inst Trans25.20% Short Interest0.50M Perf Half Y55.97%
Book/sh0.52 P/B7.29 EPS next Y21.60% ROA-69.30% Target Price20.67 Perf Year5.87%
Cash/sh1.46 P/C2.60 EPS next 5Y- ROE-207.10% 52W Range2.19 - 5.80 Perf YTD23.05%
Dividend- P/FCF- EPS past 5Y19.50% ROI-190.00% 52W High-34.66% Beta1.30
Dividend %- Quick Ratio4.70 Sales past 5Y11.10% Gross Margin- 52W Low73.06% ATR0.28
Employees57 Current Ratio4.70 Sales Q/Q250.00% Oper. Margin- RSI (14)46.99 Volatility7.06% 7.34%
OptionableYes Debt/Eq0.00 EPS Q/Q31.90% Profit Margin- Rel Volume0.77 Prev Close3.61
ShortableYes LT Debt/Eq0.00 EarningsAug 08 BMO Payout- Avg Volume143.06K Price3.79
Recom1.70 SMA20-6.54% SMA501.94% SMA20016.84% Volume109,777 Change4.99%
Date Action Analyst Rating Change Price Target Change
Nov-11-20Upgrade Cantor Fitzgerald Neutral → Overweight $4
Sep-18-20Initiated B. Riley FBR Buy $5
Feb-10-20Initiated SVB Leerink Outperform $6
Dec-10-19Resumed Cantor Fitzgerald Neutral $2 → $4
Aug-15-19Downgrade Maxim Group Buy → Hold
Aug-12-19Downgrade Cantor Fitzgerald Overweight → Neutral $29 → $2
Jul-26-19Downgrade Mizuho Buy → Neutral $17 → $4
Jun-27-19Initiated Mizuho Buy
Oct-12-18Initiated Mizuho Buy $17
Jun-05-18Initiated Seaport Global Securities Buy $29
Sep-12-23 12:48PM
Sep-07-23 07:30AM
Aug-30-23 07:30AM
Aug-11-23 07:41AM
08:27AM Loading…
Aug-08-23 08:27AM
Jul-28-23 07:30AM
Jul-19-23 08:30AM
Jul-07-23 08:30AM
Jul-03-23 08:45AM
Jun-09-23 07:30AM
Jun-01-23 07:30AM
May-30-23 08:00AM
May-25-23 12:27AM
07:30AM Loading…
May-22-23 07:30AM
May-16-23 09:00AM
May-13-23 08:15AM
May-11-23 07:54AM
Apr-18-23 07:15AM
Apr-10-23 07:30AM
Mar-31-23 06:22AM
Mar-29-23 07:30AM
Mar-24-23 07:30AM
Mar-16-23 07:30AM
Mar-14-23 07:30AM
Nov-14-22 07:30AM
Nov-08-22 02:28PM
12:44PM Loading…
Nov-03-22 12:44PM
Oct-19-22 07:30AM
Oct-04-22 07:30AM
Sep-22-22 07:30AM
Sep-13-22 07:30AM
Sep-08-22 08:48AM
Aug-11-22 07:30AM
Jul-20-22 07:30AM
Jun-24-22 10:08AM
Jun-13-22 01:27PM
Jun-10-22 03:30PM
Jun-08-22 01:21PM
Jun-06-22 02:04PM
Jun-01-22 02:25PM
May-31-22 02:27PM
May-25-22 02:29PM
May-23-22 03:32PM
May-19-22 03:02PM
May-18-22 03:12PM
May-17-22 09:27AM
May-13-22 07:30AM
May-12-22 02:47PM
May-11-22 02:28PM
May-10-22 02:36PM
May-06-22 03:48PM
May-04-22 07:30AM
May-03-22 07:00AM
Apr-29-22 09:00AM
Apr-19-22 10:51AM
Mar-31-22 07:30AM
Mar-28-22 11:20AM
Mar-14-22 07:30AM
Jan-25-22 10:00AM
Dec-22-21 07:30AM
Dec-17-21 09:00AM
Dec-16-21 04:01PM
Dec-02-21 07:25AM
Nov-19-21 10:00AM
Nov-18-21 07:30AM
Nov-17-21 07:30AM
Nov-16-21 07:30AM
Nov-15-21 07:45AM
Oct-21-21 07:30AM
Oct-13-21 07:30AM
Oct-12-21 07:30AM
Sep-21-21 04:01PM
Sep-07-21 07:30AM
Aug-10-21 07:30AM
Jul-28-21 04:01PM
Jul-26-21 07:30AM
Jul-23-21 07:30AM
Jul-07-21 12:02PM
Jun-14-21 10:00AM
Jun-02-21 07:30AM
May-26-21 07:30AM
May-25-21 07:30AM
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Amoroso MichaelDirectorSep 20Sale3.903271,275114,465Sep 22 04:05 PM
Vazzano Joseph WalterChief Financial OfficerSep 19Buy3.823,00011,458238,179Sep 20 09:00 AM
O'Malley Brendan M.SVP, General CounselSep 18Buy3.803,00011,400187,421Sep 19 09:00 AM
Amoroso MichaelDirectorJun 20Sale4.453381,504114,792Jun 21 04:05 PM
Alvino MarkDirectorApr 25Sale3.258872,88317,527May 05 04:05 PM
Amoroso MichaelDirectorMar 20Sale2.3326862456,441Mar 21 05:13 PM
Amoroso MichaelDirectorMar 03Sale2.381,0022,38556,709Mar 03 07:06 PM
O'Malley Brendan M.SVP, General CounselDec 09Buy3.135,86918,37093,830Dec 12 04:10 PM
O'Malley Brendan M.SVP, General CounselNov 18Buy3.997,50029,92587,961Nov 21 09:00 AM
Vazzano Joseph WalterChief Financial OfficerNov 18Buy4.002,50010,00095,250Nov 21 09:00 AM